Publication:
Investigation of therapeutic effects of α-mangostin on thioacetamide-induced cirrhosis in rats

0
0

Issued Date

2015

Resource Type

Article

File Type

application/pdf

ISSN

1252208

Other identifier(s)

2-s2.0-84957672524

Rights Holder(s)

Scopus

Bibliographic Citation

Journal of the Medical Association of Thailand. Vol 98, (2015), p.S91-S97

Suggested Citation

Sukseree S., Sophonnithiprasert T., Pradidarcheep W., Nilbunga S., Nilwarangoon S., Watanapokasin R. Investigation of therapeutic effects of α-mangostin on thioacetamide-induced cirrhosis in rats. Journal of the Medical Association of Thailand. Vol 98, (2015), p.S91-S97. Retrieved from: https://hdl.handle.net/20.500.14740/6061

Title

Investigation of therapeutic effects of α-mangostin on thioacetamide-induced cirrhosis in rats

Author(s)

Sukseree S.
 Sophonnithiprasert T.
 Pradidarcheep W.
 Nilbunga S.
 Nilwarangoon S.
 Watanapokasin R.

Abstract

To determine the effects of alpha-mangostin on thioacetamide (TAA)-induced liver cirrhosis in rats. Material and Method: Male Wistar rats were divided into 3 groups and treated with intraperitoneal injections of TAA (200 mg/kg) 3 times per week for per week for 8, 12 and 16 weeks, respectively. One subgroup was left untreated whereas the other two were treated either with 100 mg/kg α-mangostin or vehicle alone (80% DMSO, 20% water), which were administered intraperitoneally 3 times per week for a total of 4 weeks. The incidence of fibrotic nodules on the liver and the serum levels of the liver enzymes aspartate transaminase (AST) and alanine transaminase (ALT) were measured. Moreover, the liver cirrhosis-related genes expression and p53 protein level in liver were analyzed by quantitative reverse transcription PCR and Western blot analysis, respectively. Results: Fibrotic nodules on the liver were formed upon treatment with TAA for 12 or 16 weeks. The nodules were then reduced by treatment with α-mangostin as compared to treatment with the vehicle DMSO. Moreover, the serum levels of the liver enzymes AST and ALT after treatment with α-mangostin decreased as compared to DMSO alone. The liver cirrhosisrelated genes expression showed no significant differences, whereas the p53 protein level in liver showed that α-mangostin reduced risk of liver fibrosis through the decrease in p53 expression as compared to the TAA_DMSO treatment. Conclusion: The results suggest that α-mangostin has a beneficial therapeutic effect in the TAA liver cirrhosis model. Further investigations on mechanisms of α-mangostin as therapeutic agent should be determined. © 2015, Medical Association of Thailand. All rights reserved.

Subject(s)

Alanine aminotransferase
 Alpha mangostin
 Aspartate aminotransferase
 Beta actin
 Collagen type 1
 Inducible nitric oxide synthase
 Interleukin 1beta
 Plant medicinal product
 Protein p53
 Thioacetamide
 Tumor necrosis factor alpha
 Unclassified drug
 Alanine aminotransferase
 Aspartate aminotransferase
 Mangostin
 Thioacetamide
 Xanthone derivative
 Animal model
 Animal tissue
 Article
 Chemoluminescence
 Controlled study
 Gene expression
 Gene sequence
 Liver cirrhosis
 Liver fibrosis
 Male
 Nonhuman
 Protein expression
 Rat
 Reverse transcription polymerase chain reaction
 Signal transduction
 Western blotting
 Animal
 Blood
 Liver cirrhosis
 Wistar rat
 Alanine Transaminase
 Animals
 Aspartate Aminotransferases
 Liver Cirrhosis
 Male
 Rats
 Rats, Wistar
 Thioacetamide
 Xanthones

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/6061

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By